MAIN RESULTS OBTAINED BY REGHEALTH-RI PROJECT ON:

Joaquín Guinea20th October, 2016

• Participation of regions/countries in the Societal Challenge 1 "Health, demographic change and well-being" of H2020

• Synergies between Horizon 2020 (H2020) and European Structural and Investment Funds (ESIFs)

• Health research and innovation in EU less-performing countries and regions

BACKGROUND

STATE OF THE ART OF HEALTH RESEARCH AND INNOVATION IN EU REGIONS

CONTENT INDEX

1. INTRODUCTION1.1. Importance of health R&I in Europe1.2. The concept of health1.3. Methodology2. SITUATION OF HEALTH RESEARCH & INNOVATION IN EUROPE 2.1. Research & Innovation in EU Countries

2.1.1. R&I Inputs2.1.2. R&I Actors and Activities2.1.3. R&I Outputs2.1.4. Performance in EU Research Framework Programmes2.1.5. Innovation Component

2.2. Research & Innovation in EU Regions2.2.1. R&I Actors and Activities2.2.2. R&I Outputs2.2.3. Performance in EU Research Framework Programmes2.2.4. Innovation Component

3. ANALYSIS OF HEALTH RESEARCH & INNOVATION IN EUROPE3.1. Detection of common patterns and analysis of key variables on Health R&I within the less performing EU regions3.2. Determinants of Health publishing propensity at the EU regional level3.3. A proposal for a Composite Indicator of Health Research Excellence4. CONCLUSIONS AND POLICY RECOMMENDATIONS5. BIBLIOGRAPHIC REFERENCES6. ANNEXES

* Health, demographic change and wellbeing

Source: European Union OpenData Portal

CORDIS - EU research projects under Horizon 2020 (2014-2020)

Modified Date: 2016-05-10

https://data.europa.eu/euodp/en/data/dataset/cordis-h2020projects-under-horizon-2020-2014-2020

BACKGROUND: Results of 2014-2015 calls of the "Health, demographic change and well-

being"* of H2020 Soc. Challenge 1 [SME instrument (PHC-12-2015-1) not included]

BACKGROUND: Survey responses from 60 Institutions from 20 Europeancountries (Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Macedonia, Malta, Netherlands, Portugal, Romania, Slovenia, Spain, Sweden and UK) and from 4 European organizations (EUREGHA, EFPIA, COST and EC).

• Regional/National/EU Agencies & Funding Institutions: 33 (55 %)

• Public Research Organizations: 18 (30%)

• Industry & Business Sector: 9 (15 %)

Institution Type

• Extremely populated scientific field generating a high competition to get funding

• Discouragement coming from low success rate

• Lack of expertise to prepare consistent proposals

• Large and complex topics more suited for the participation of reputed organizations from elite EU regions

• Lack of specific support to prepare the proposals

• Low expected reward in relation to the effort for preparing and implementing the projects/proposals

Most significant and influential factors hindering the participation of EU less-

performing regions/countries in the Societal Challenge 1 "Health, demographic

change and well-being" of Horizon 2020 (H2020)

• Design suitable actions/programmes (similar to Widening) specifically requiring the participation of less-performing regions

• Promote networking activities with elite institutions of EU leading regions

• Provide alternative funding for high quality proposals presented in H2020 that have not been successful

• Providing guidance and support by means of consultancy or any other services facilitating the elaboration of competitive proposals

• Foster mobility of researchers to excellent institutions in EU less-performing regions

• Design of more specific and suitable topics more accessible to less-performing regions

• Rewarding research teams working on H2020 with quality proposals not being funded by means of bonuses or awards

• Change/improve the methodology of evaluation of the proposals

• Allow (by the EC financial rules) the personal costs calculation in RIA, etc., in the similar way to MSCA

Potential actions for increasing the participation of less-performing

regions/countries in the Societal Challenge 1 "Health, demographic change and

well-being" of H2020

• The very high difficulty in obtaining H2020 funding from EU less performing regions institutions (Public Research Centres, Universities, Hospitals, Industry, etc.) is probably the main trouble for reaching such synergies. It seems obvious that without H2020 funding there is not possibility of synergies

• Significant conceptual and strategic differences between H2020 (excellent research) and ESIF (regional capacity building and overcome structural difference) make those synergies also difficult to achieve

• There are also important organizational and administrative differences between H2020 and ESIF in terms of timing, different cost definitions and financial management rules, etc., which makes synergies a rather complicated business

Features identified as more important and influential in hindering synergies

between Horizon 2020 and European Structural and Investment Funds (ESIFs)

http://s3platform.jrc.ec.europa.eu/synergies-tool

Total ESIF Research & Innovation € per capita per year (planned R&I-related investments under ESIF 2014-2020)

Total H2020 € per capita per year (allocated funding 2014-March 2016 to all type of

actions&thematic areas)

Available data from 194 EU Regions (18/10/2016)

Regions&countries that have selected public health & security as priority for their innovation

strategies for smart specialization (RIS3)

http://s3platform.jrc.ec.europa.eu/map

vs

EU Regions ordered by H2020 funding (increasing order)

Total H2020 € per capita per year (allocated funding 2014-March 2016 to all type of

actions&thematic areas)

Total ESIF Research & Innovation € per capita per year (planned R&I-related

investments under ESIF 2014-2020)

% H2020Health as RIS3

priority

1 Podlaskie PL 0,00 63,01 0,0% Yes2 Lubuskie PL 0,00 52,18 0,0% Yes3 Opolskie PL 0,00 50,86 0,0% Yes4 Ciudad Autonoma De Melilla ES 0,00 18,30 0,0% ?5 Ciudad Autonoma De Ceuta ES 0,00 15,34 0,0% ?6 Severozapaden BG 0,00 13,05 0,0% Yes7 Åland FI 0,00 7,15 0,0% Yes8 Swietokrzyskie PL 0,00 65,15 0,0% Yes9 Yugoiztochen BG 0,01 12,83 0,0% Yes

10 Podkarpackie PL 0,01 65,41 0,0% Yes11 Severen Tsentralen BG 0,02 12,95 0,2% Yes12 Kujawsko-Pomorskie PL 0,04 49,20 0,1% Yes13 Sud-Vest Oltenia RO 0,04 7,57 0,6% Yes14 Extremadura ES 0,08 37,85 0,2% No15 Sud - Muntenia RO 0,08 7,56 1,1% Yes16 Zapadne Slovensko SK 0,11 54,83 0,2% No17 Zachodniopomorskie PL 0,12 49,39 0,3% Yes18 Nord-Vest RO 0,12 7,47 1,6% Yes19 Severozapad CZ 0,12 44,84 0,3% Yes20 Vychodne Slovensko SK 0,14 54,21 0,3% No21 Centru RO 0,15 7,78 1,8% Yes22 Regiao Autonoma Dos Acores PT 0,17 121,27 0,1% Yes23 Burgenland AT 0,19 7,78 2,4% Yes24 Vest RO 0,20 7,39 2,6% Yes25 Stredni Cechy CZ 0,20 43,95 0,5% Yes26 Eszak-Magyarorszag HU 0,21 49,65 0,4% Yes27 Del-Alfold HU 0,22 49,38 0,4% Yes28 Slaskie PL 0,24 49,16 0,5% Yes29 Limousin FR 0,25 10,28 2,4% Yes30 Yuzhen Tsentralen BG 0,27 13,19 2,0% Yes

vs

EU Regions ordered by H2020 funding (increasing order)

Total H2020 € per capita per year (allocated funding 2014-March 2016 to all type of

actions&thematic areas)

Total ESIF Research & Innovation € per capita per year (planned R&I-related

investments under ESIF 2014-2020)

% H2020Health as RIS3

priority

31 Champagne-Ardenne FR 0,28 8,27 3,3% No

32 Nyugat-Dunantul HU 0,28 49,27 0,6% Yes

33 Severoiztochen BG 0,28 12,82 2,2% Yes

34 Sud-Est RO 0,28 7,44 3,7% Yes

35 Kozep-Dunantul HU 0,29 49,28 0,6% Yes

36 Stredni Morava CZ 0,32 44,74 0,7% Yes

37 Stredne Slovensko SK 0,34 54,49 0,6% No

38 Valle dAosta IT 0,35 11,29 3,0% No

39 Notio Aigaio EL 0,37 11,32 3,2% No

40 Corse FR 0,39 10,14 3,7% No

41 Lodzkie PL 0,41 57,41 0,7% Yes

42 Eszak-Alfold HU 0,42 49,20 0,8% Yes

43 Warminsko-Mazurskie PL 0,43 72,11 0,6% Yes

44 Nord-Est RO 0,44 7,83 5,3% Yes

45 Calabria IT 0,45 24,86 1,8% Yes

46 Jihozapad CZ 0,46 44,87 1,0% Yes

47 Molise IT 0,48 11,51 4,0% Yes

48 Del-Dunantul HU 0,53 49,69 1,1% Yes

49 Poitou-Charentes FR 0,58 5,79 9,1% Yes

50 Abruzzo IT 0,62 9,08 6,4% Yes

51 Islas Baleares ES 0,65 7,95 7,6% Yes

52 Smaland och oarna SE 0,69 8,78 7,3% Yes

53 Haute-Normandie FR 0,70 10,27 6,4% Yes

54 Basse-Normandie FR 0,74 7,89 8,5% Yes

55 Lubelskie PL 0,76 59,84 1,3% Yes

56 Moravskoslezsko CZ 0,76 44,86 1,7% Yes

57 Sicilia IT 0,77 25,75 2,9% No

58 Dolnoslaskie PL 0,79 45,26 1,7% Yes

59 Lietuva LT 0,82 48,61 1,7% Yes

60 Severovychod CZ 0,91 44,56 2,0% Yes

vs

EU Regions ordered by H2020 funding (increasing order)

Total H2020 € per capita per year (allocated funding 2014-March 2016 to all type of

actions&thematic areas)

Total ESIF Research & Innovation € per capita per year (planned R&I-related

investments under ESIF 2014-2020)

% H2020Health as RIS3

priority

61 Pomorskie PL 0,91 48,55 1,8% Yes

62 Puglia IT 0,93 26,65 3,4% Yes

63 Picardie FR 0,93 8,05 10,4% Yes

64 Bourgogne FR 0,95 4,99 16,0% Yes

65 Lorraine FR 0,96 4,10 19,0% Yes

66 Sachsen-Anhalt DE 1,04 27,88 3,6% Yes

67 Wielkopolskie PL 1,04 50,16 2,0% Yes

68 Regiao Autonoma Da Madeira PT 1,05 30,58 3,3% Yes

69 Franche-Comte FR 1,16 10,05 10,3% No

70 Centre FR 1,19 4,02 22,8% No

71 Castilla-La Mancha ES 1,24 24,19 4,9% Yes

72 Campania IT 1,30 23,90 5,2% Yes

73 Alentejo PT 1,44 94,68 1,5% Yes

74 Hrvatska HR 1,45 28,56 4,8% Yes

75 Basilicata IT 1,45 30,95 4,5% No

76 Marche IT 1,45 6,92 17,3% Yes

77 Malopolskie PL 1,48 51,39 2,8% Yes

78 Nord - Pas-De-Calais FR 1,49 6,51 18,6% Yes

79 Voreio Aigaio EL 1,60 29,95 5,1% No

80 Canarias ES 1,65 22,63 6,8% Yes

81 Principado de Asturias ES 1,73 15,64 10,0% Yes

82 Sjaelland DK 1,84 7,52 19,7% Yes

83 La Rioja ES 1,89 15,99 10,6% No

84 Bolzano IT 1,90 5,18 26,8% Yes

85 Andalucia ES 1,90 26,19 6,8% Yes

86 Yugozapaden BG 1,91 13,09 12,7% Yes

87 Auvergne FR 1,93 7,13 21,3% Yes

88 Vorarlberg AT 1,96 4,34 31,1% Yes

89 Pays De La Loire FR 2,02 5,60 26,5% Yes

90 Region De Murcia ES 2,02 25,22 7,4% Yes

vs

EU Regions ordered by H2020 funding (increasing order)

Total H2020 € per capita per year (allocated funding 2014-March 2016 to all type of

actions&thematic areas)

Total ESIF Research & Innovation € per capita per year (planned R&I-related

investments under ESIF 2014-2020)

% H2020Health as RIS3

priority

91 Umbria IT 2,13 10,87 16,4% No

92 Latvija LV 2,21 47,99 4,4% No

93 Mazowieckie PL 2,23 31,28 6,7% Yes

94 Saarland DE 2,29 ,16 24,2% Yes

95 Schleswig-Holstein DE 2,39 8,60 21,7% Yes

96 Veneto IT 2,41 4,25 36,2% No

97 Mecklenburg-Vorpommern DE 2,52 25,72 8,9% Yes

98 Wales UK 2,68 24,61 9,8% Yes

99 Algarve PT 2,73 28,49 8,8% Yes

100 Brandenburg DE 2,76 26,20 9,5% Yes

101 Jihovychod CZ 2,81 44,82 5,9% Yes

102 North West (England) UK 2,85 2,65 51,8% Yes

103 Rheinland-Pfalz DE 2,86 3,62 44,1% Yes

104 Galicia ES 2,88 17,64 14,0% Yes

105 Aquitaine FR 2,91 8,99 24,5% No

106 Languedoc-Roussillon FR 2,97 6,15 32,6% No

107 Thuringen DE 3,00 26,79 10,1% Yes

108 Castilla Y Leon ES 3,00 13,99 17,7% Yes

109 Malta MT 3,00 26,29 10,3% Yes

110 Etela-Suomi FI 3,04 12,71 19,3% No

111 Bretagne FR 3,06 4,22 42,0% Yes

112 Friuli-Venezia Giulia IT 3,08 9,64 24,2% No

113 Niedersachsen DE 3,34 4,77 41,1% Yes

114 Sardegna IT 3,35 15,07 18,2% Yes

115 Norra Mellansverige SE 3,39 16,18 17,3% Yes

116 Norte PT 3,70 73,15 4,8% Yes

117 Northern Ireland UK 3,76 17,23 17,9% Yes

118 Centro PT 3,89 62,85 5,8% Yes

119 Provence-Alpes-Côte Dazur FR 3,91 3,42 53,3% Yes

120 Hessen DE 3,93 2,71 59,2% Yes

vs

EU Regions ordered by H2020 funding (increasing order)

Total H2020 € per capita per year (allocated funding 2014-March 2016 to all type of

actions&thematic areas)

Total ESIF Research & Innovation € per capita per year (planned R&I-related

investments under ESIF 2014-2020)

% H2020Health as RIS3

priority

121 Bucuresti - Ilfov RO 4,05 12,63 24,3% Yes

122 Comunidad Valenciana ES 4,10 13,37 23,5% Yes

123 Tirol AT 4,23 4,70 47,4% Yes

124 Pohjois- Ja Ita-Suomi FI 4,27 13,69 23,7% No

125 Midi-Pyrenees FR 4,35 3,42 56,0% Yes

126 Cantabria ES 4,36 10,32 29,7% Yes

127 East Midlands (England) UK 4,39 4,79 47,8% Yes

128 Niederosterreich AT 4,39 4,86 47,4% Yes

129 West Midlands (England) UK 4,43 2,53 63,7% Yes

130 Emilia-Romagna IT 4,59 2,98 60,7% Yes

131 Syddanmark DK 4,64 4,95 48,4% Yes

132 Kozep-Magyarorszag HU 4,69 4,92 48,8% Yes

133 Region Wallonne BE 4,71 9,06 34,2% Yes

134 North East (England) UK 4,94 2,60 65,5% Yes

135 Bratislavsky Kraj SK 5,11 37,57 12,0% Yes

136 Lombardia IT 5,13 3,50 59,5% Yes

137 Oberosterreich AT 5,13 4,52 53,2% Yes

138 Yorkshire and The Humber UK 5,35 2,60 67,3% Yes

139 Alsace FR 5,50 2,97 64,9% No

140 Nordrhein-Westfalen DE 5,74 5,75 50,0% Yes

141 Lansi-Suomi FI 5,76 13,38 30,1% No

142 Rhone-Alpes FR 5,82 3,90 59,9% Yes

143 Mellersta Norrland SE 6,39 24,09 21,0% Yes

144 Aragon ES 6,42 8,50 43,0% No

145 Karnten AT 6,48 5,10 56,0% Yes

146 Piemonte IT 6,56 6,71 49,5% Yes

147 Salzburg AT 6,73 4,73 58,7% Yes

148 Sachsen DE 6,87 29,98 18,6% Yes

149 Toscana IT 7,09 6,54 52,0% No

150 Hamburg DE 7,22 2,54 73,9% Yes

vs

EU Regions ordered by H2020 funding (increasing order)

Total H2020 € per capita per year (allocated funding 2014-March 2016 to all type of

actions&thematic areas)

Total ESIF Research & Innovation € per capita per year (planned R&I-related

investments under ESIF 2014-2020)

% H2020Health as RIS3

priority

161 Noord-Nederland NL 9,05 8,63 51,2% Yes

162 Eesti EE 9,05 100,71 8,2% Yes

163 Scotland UK 9,30 7,02 57,0% Yes

164 Nordjylland DK 9,33 4,51 67,4% Yes

165 Lisboa PT 9,77 15,13 39,2% Yes

166 Vastsverige SE 10,33 5,66 64,6% Yes

167 Cataluna ES 10,42 13,29 44,0% Yes

168 Vlaams Gewest BE 10,86 3,82 74,0% Yes

169 Sydsverige SE 11,13 4,53 71,1% Yes

170 Attiki EL 11,29 9,08 55,4% No

171 Zuid-Nederland NL 11,41 5,46 67,6% Yes

172 Comunidad De Madrid ES 11,49 8,58 57,2% Yes

173 Östra Mellansverige SE 11,59 4,53 71,9% Yes

174 Bayern DE 11,79 2,42 82,9% Yes

175 Midtjylland DK 11,90 4,50 72,6% Yes

176 Berlin DE 12,11 15,43 44,0% Yes

177 Oost-Nederland NL 12,19 5,90 67,4% Yes

178 London UK 12,80 4,68 73,2% Yes

179 Kypros CY 13,68 12,77 51,7% Yes

180 Kriti EL 14,04 16,24 46,4% No

181 Southern and Eastern IE 15,24 4,81 76,0% Yes

182 Trento IT 16,01 11,08 59,1% Yes

183 Ile De France FR 16,36 1,09 93,7% Yes

184 Pais Vasco ES 16,80 12,34 57,7% Yes

185 Luxembourg LU 18,07 2,89 86,2% Yes

186 West-Nederland NL 18,49 2,57 87,8% Yes

187 Stockholm SE 19,35 2,66 87,9% Yes

188 Steiermark AT 20,66 4,82 81,1% Yes

189 Övre Norrland SE 20,95 34,03 38,1% Yes

190 Bremen DE 20,97 13,01 61,7% Yes

191 Wien AT 22,70 4,79 82,6% Yes

192 Hovedstaden DK 28,25 4,53 86,2% Yes

193 Helsinki-Uusimaa FI 32,46 12,49 72,2% Yes

194 Region De Bruxelles-Capitale BE 37,97 4,85 88,7% Yes

• Design appropriate (i.e. more flexible) bureaucratic and administrative procedures of ESIFs funding in order to facilitate synergies and complementary use of various funding sources

• Provide appropriate information and support on synergies to those institutions interested toparticipate in H2020 and/or ESIFs

• Coordinate the timing of calls of the regional programmes with those of H2020

• Align the regional research and innovation policy with the H2020

• Increase the number of H2020 topics/actions/areas/etc. specifically designed to promote and/orfacilitate synergies between H2020 and ESIFs

• Training and incentives to policy makers, managing authorities and intermediary bodies at memberstate level

• Force the Seal of Excellence tool to national governments via ESIF for appropriate programmes

Potential actions for improving the synergies between Horizon 2020 and

European Structural and Investment Funds (ESIFs)

• Brain drain in the field of health research in a region/country

• Low understanding of specific research and innovation issues by policy and decision makers

• Insufficient knowledge transfer from public research organizations to interested stakeholders

• Poor investment in public research and, above all, in private research

• Insufficient linkages with excellent organizations, companies, etc., from advanced and leading European regions and countries (international collaboration)

Key issues identified as the main negative factors hindering health research and

innovation progress of in EU less-performing countries/regions

• Promote collaborative actions between leading and less-performing European regions

• Design research programmes aimed at fostering the stay/return of researchers in the region/country

• Improve the alignment or interlink between innovation and research policy

• Compile better data on innovation both at national and regional level

• Increase the resources for specific research and innovation instruments

• Analyze private sector and society needs/concerns in order to be fitted to research and innovation activities in public sector (PROs and universities)

• Elaborate clear and easy-to-understand materials (guides, policy briefs, ...) and implement training activities for policy and decision makers in order to support and facilitate a better understanding of research and innovation processes

• Study the ‘Brain Drain’ phenomenon in-depth

• Help with long-term basic national problems like salary limits in some low performing countries

Potential actions for improving the health research and innovation situation in

EU less-performing countries and regions

FINAL KEY MESSAGES/RECOMMENDATIONS

TO DG RESEARCH&INNOVATION: • ALLOCATE A MINIMUM OF 5% OF THE H2020 “HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING” BUDGET SPECIFICALLY TO LESS PERFORMING EUROPEAN REGIONS/COUNTRIES TO REDUCE THE INCREASING GAP IN HEALTH RESEARCH AND INNOVATION IN EU

TO DG REGIO:

TO REGIONAL/NATIONAL HEALTH RESEARCH&INNOVATION AUTHORITIES:

• DESIGN APPROPRIATE (I.E. MORE FLEXIBLE) BUREAUCRATIC AND ADMINISTRATIVE PROCEDURES OF ESIFs FUNDING IN ORDER TO FACILITATE THE SYNERGIES AND COMPLEMENTARY USE OF DIFFERENT FUNDING SOURCES

• IMPROVE THE ALIGNMENT AND INTERLINK BETWEEN HEALTH RESEARCH AND HEALTH INNOVATION POLICIES

• DESIGN RESEARCH AND INNOVATION PROGRAMMES AIMED AT FOSTERING THE STAY/RETURN OF RESEARCHERS IN THE REGION/COUNTRY

• INNOVATEC (Spain)• European Regional and Local Health Authorities

(EUREGHA) (EU)• University of Trieste (Italy)• Association of Research Based Pharmaceutical

Manufacturers (ARPharM) (Bulgaria)• Health ClusterNET (Netherlands)• Libertas International University (Croatia)• Polish Academy of Sciences /Nencki Institute

(Poland)• Ministry of Finance and Public Administration

(Spain)• University of Tartu (Estonia)• Academy of Sciences of the Czech Republic

(Czech Republic)• Agencia de Innovación, Financiación e

Internacionalización Empresarial de Castilla y León (Spain)

• Agencia Estatal Consejo Superior de Investigaciones Científicas (CSIC), (Spain)

• Agency for Healthcare Quality & Assessment of Catalonia (Spain)

• Portuguese National Innovation Agency (ANI) (Portugal)

• Bayer AG/ European Federation of Pharmaceutical Industries and Associations (EFPIA) (Germany / EU)

• Comission for Coordination and Regional Dev. of the Algarve) (Portugal)

• Consejería Igualdad, Salud y Políticas Sociales-Junta de Andalucía (Spain)

• Democritus University of Thrace (Greece)• Department of Health Care, region Västra

Götaland (Sweden)• Department of Informatics Ionian University

Corfu (Greece)• Digital Health Institute, Scotland (UK)• EIT Health KIC (Hungary)• Estonian Research Council (Estonia)• Eurasante / NHL Cluster (France)• European Commission - DG Research&Innov.

(EU)• European Commission - DG CONNECT (EU)• European Commission - IPTS (EU)• Spanish Ministry of Economy and

Competitiveness (Spain) / COST (EU)• Fundación Publica Andaluza Progreso y Salud

(Spain)• Health Institute 'Carlos III' (ISCIII), (Spain)• Inkubator D.o.o. Sežana (Slovenia)• Inst. Podstawowych Problemów Techniki Polskiej

Akademii Nauk. (Poland)• Italian Ministry of Health (Italy)• Junta de Castilla y León (Spain)• Klaster LifeScience Krakow (Poland)• Logotech SA (Greece)• London School of Hygiene and Trop. Medicine

(UK)• Macedonian Academy of Sciences and Arts,

Research Centre "Georgi D. Efremov" (Macedonia)

• Marche Region, Industrial Research and

Innovation Office (Italy)• Marshal Office of Świętokrzyskie Region (Poland)• Marshal Office of the Lubelskie Voivodeship

(Poland)• MidTECH Innovations (UK)• Ministry of Science, Education and Sports

(Croatia)• National Authority for Scientific Research and

Innovation (Romania)• National Documentation Centre (Greece)• North East Regional Development Agency

(Romania)• Ovidius University Constanta (Romania)• Riga Stradins University (Latvia)• South Moravian Center for International

Mobility, Brno, Czech Republic (Czech Republic)• South Transdanubian Regional Development

Agency (Hungary)• St. Anne's University Hospital in Brno-Int. Clinical

Research Center (Czech Republic)• State Education Development Agency (Latvia)• Technology Centre of the Czech Academy of

Sciences (Czech Republic)• The Innovative Pharmaceutical Industry

Association (Lithuania)• University of Algarve (Portugal)• University of Malta (Malta)• University of Nova Gorica (Slovenia )• University of Pécs (Hungary)• Upper Silesian Agency for Entrepreneurship and

Development Ltd. (Poland)